A Survey of Provider-Reported Use and Perceived Effectiveness of Medications for Symptom Management in Telemedicine and Outpatient Visits for Mild COVID-19
Open Access
- 22 March 2021
- journal article
- research article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 10 (2) , 839-851
Abstract
Introduction Many patients with mild coronavirus disease 2019 (COVID-19) have symptoms requiring acute and follow-up care. The aims of this study were to assess (1) provider-reported use of medications and their perceived effectiveness and (2) degree of difficulty managing specific symptoms at episodic COVID-19 care sites and in a longitudinal monitoring program. Methods We sent an online survey to physicians, advanced practice providers, and registered nurses redeployed to COVID-19 care sites at an academic medical center from March to May 2020. We asked about the use of medications and perceived effectiveness of medications to treat symptoms of COVID-19 and the perceived challenge of symptom management. Comparison was made by provider type (episodic or longitudinal site of care). Results Responses from 64 providers were included. The most frequently used medications were acetaminophen (87.1% of respondents), benzonatate (83.9%), and albuterol metered dose inhalers (MDI) (80.6%). Therapies for lower respiratory tract symptoms were reported as more commonly used by longitudinal follow-up providers compared to episodic providers including guaifenesin (90.6% vs 60.0%, p = 0.007), benzonatate (93.8% vs 73.3%, p = 0.04), nebulized albuterol for patients with asthma (75.0% vs 43.3%, p = 0.019), and albuterol MDIs for patients without asthma (90.6% vs 66.7%, p = 0.029). Medications found to have the highest perceived efficacy by respondents using the therapy (> 80% reporting “very efficacious”) included albuterol, acetaminophen for fever, non-sedating antihistamines, nasal steroid spray, and non-steroidal anti-inflammatory drugs (NSAIDs) for myalgia, arthralgia, or headache. Lower respiratory symptoms and anxiety were rated as the most challenging symptoms to manage. Conclusions Providers reported that clinical care of mild COVID-19 with medications in common use for other respiratory infections is effective, both at episodic care and longitudinal sites of care, but that specific symptoms are still challenging to manage.Keywords
Funding Information
- Health Resources and Services Administration (T1MHP39056)
- Paul W. Seavey Internal Medicine Clinic research fund
This publication has 13 references indexed in Scilit:
- Digital Health Technology and Telemedicine-Based Hospital and Home Programs in Pulmonary Medicine During the COVID-19 PandemicAmerican Journal of Therapeutics, 2021
- Prolonged Symptoms After COVID-19 Infection in OutpatientsOpen Forum Infectious Diseases, 2021
- Mild or Moderate Covid-19New England Journal of Medicine, 2020
- Physicians’ Perspectives on COVID-19: An International SurveyHealthcare, 2020
- The Early Natural History of SARS-CoV-2 InfectionMayo Clinic Proceedings, 2020
- Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid reviewBMJ, 2020
- Non-steroidal anti-inflammatory drugs and covid-19BMJ, 2020
- Current perspective on pandemic of COVID-19 in the United StatesJournal of Family Medicine and Primary Care, 2020
- Over-the-counter (OTC) medications for acute cough in children and adults in community settingsCochrane Database of Systematic Reviews, 2014
- Physician Specialty Is Associated With Differences in the Evaluation and Management of Acute Bacterial RhinosinusitisJAMA Otolaryngology–Head & Neck Surgery, 2002